Bailard Inc. Boosts Position in Sanofi (NASDAQ:SNY)

Bailard Inc. boosted its stake in Sanofi (NASDAQ:SNY) by 1.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 16,359 shares of the company’s stock after buying an additional 220 shares during the quarter. Bailard Inc.’s holdings in Sanofi were worth $789,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Financial Advocates Investment Management boosted its holdings in Sanofi by 3.4% in the third quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock valued at $365,000 after acquiring an additional 206 shares during the last quarter. US Bancorp DE lifted its stake in shares of Sanofi by 8.6% in the third quarter. US Bancorp DE now owns 111,405 shares of the company’s stock worth $6,420,000 after acquiring an additional 8,813 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Sanofi by 12.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,861 shares of the company’s stock valued at $165,000 after buying an additional 309 shares during the last quarter. QRG Capital Management Inc. increased its position in shares of Sanofi by 8.7% in the 3rd quarter. QRG Capital Management Inc. now owns 152,406 shares of the company’s stock worth $8,783,000 after purchasing an additional 12,245 shares during the last quarter. Finally, Garrison Asset Management LLC acquired a new stake in Sanofi during the third quarter valued at approximately $231,000. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Up 3.8 %

Sanofi stock opened at $56.52 on Tuesday. The company has a 50 day moving average of $51.81 and a 200-day moving average of $52.61. The stock has a market capitalization of $143.44 billion, a PE ratio of 22.70, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, equities research analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SNY. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.